Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 6 of 6 results for sodium zirconium cyclosilicate

  1. Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)

    Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults.

    Technology appraisal guidance
    Last updated
    24 January 2022
    View recommendations

    Sections for TA599

  2. The committee noted that there was no clinical evidence showing that having sodium zirconium cyclosilicate improved length or quality of life or allowed patients to stay on optimal doses of renin-angiotensin-aldosterone system (RAAS) inhibitors. It therefore considered that it would be valuable to have studies comparing sodium zirconium cyclosilicate plus standard care with standard care alone in people with confirmed hyperkalaemia of 6.0 mmol/litre and above, and that these should investigate: mortality disease progression patterns of RAAS inhibitor use healthcare utilisation, and health-related quality of life.

    noted that there was no clinical evidence showing that having sodium zirconium cyclosilicate improved length or quality of life or...

    Research recommendation
    Published
    8 November 2019

  3. Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]

    In development [GID-TA11561] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  4. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

    COVID-19 rapid guideline
    Last updated
    8 May 2024

    Sections for NG191

  5. Chronic kidney disease: assessment and management (NG203)

    This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.

    NICE guideline
    Last updated
    24 November 2021
    View recommendations

    Sections for NG203

  6. Research recommendations

    pregabalin and zonisamide. Generalised seizures: lamotrigine, levetiracetam, sodium valproate and zonisamide. CG137/1